There’s a conversation happening right now about how CMS reimbursement cuts are crushing clinics. Medicare physician payments have fallen 33% in real terms since 2001, when adjusted for practice cost inflation — according to the AMA’s own data. The median loss per physician at system-affiliated medical groups has crossed $249,000. Expenses outpacing revenue nearly 3-to-1.
All of that is true. And if you sell medical devices into those clinics, it’s also only half the story.
The other half is what happens when your buyer is financially stressed, operationally overwhelmed, and being told by their CFO to audit every vendor contract. Because that math doesn’t stop at the clinic’s front door. It flows straight through to your AR aging report, your margin, and eventually your headcount.
The Downstream Math
When a hospital or ASC sees reimbursement decline, the first move is predictable: cut supply chain costs. External spend on supplies, pharmacy, and purchased services makes up 30–40% of a typical health system’s total cost base, according to McKinsey. That’s the biggest controllable expense. It’s also the line item that includes you.
The mechanisms are already in motion. Health systems are standardizing products and consolidating suppliers — reducing the number of vendors to increase purchase volume with primary suppliers and drive contract compliance. Vizient’s Summer 2025 Spend Management Outlook forecasts medical supply chain expenses rising 2.41% in 2026, and hospitals are responding by squeezing the vendors they keep and cutting the ones they don’t.
McKinsey’s analysis is blunter: a combination of federal policy changes, tariffs, and clinical staff shortages could cut health system margins by 2 to 13 percentage points over the next five years. When margins compress that much, every vendor relationship gets re-examined.
If you’re a device company, the question isn’t whether your customers are going to renegotiate. It’s whether you’ll be on the list they consolidate toward — or the list they consolidate away from.
Orthopedics Is Ground Zero
The numbers are sharpest in orthopedics, where the gap between reimbursement and cost has been widening for two decades.
Medicare reimbursement for orthopedic subspecialties has declined 30–39% in inflation-adjusted terms since 2000. Foot and ankle surgery is down nearly 30%. Sports medicine is down 33%. Total adult reconstruction — the bread and butter of joint implant companies — is down 38.9%. Between 2012 and 2017 alone, Medicare Part B payments to surgeons for total joint arthroplasties fell 14.9% in real terms.
Implant costs haven’t dropped anywhere near that. In some ASC cases, a single specialized implant now costs more than the entire Medicare reimbursement for the procedure. Surgeons and facility administrators are caught in between — performing more procedures to make up volume while the economics of each individual case deteriorate.
For manufacturers and distributors, this creates a compounding problem. Your customer is losing money on the procedures that use your products. Every conversation about pricing now starts with “what’s your reimbursement for this?” instead of “what’s the clinical benefit?” Value-based purchasing was supposed to be a future-state concept. It’s here, and it’s being driven by necessity, not philosophy.
The Payment Chain Trap
Here’s where it gets personal — especially for distributors.
Hospital Days Payable Outstanding has been climbing — 77 days in 2022, up from 71 days in 2019. That trend hasn’t reversed. When a health system is under margin pressure, one of the easiest levers is simply paying suppliers later. It doesn’t require a board decision. It doesn’t require a vendor negotiation. The AP team just… slows down.
For manufacturers, that means consigned inventory — which they own until it’s implanted — sits in the field longer before generating revenue. A case happens on Tuesday. The invoice goes out whenever documentation is complete, which could be days or weeks later. The hospital pays 60–90 days after that. And if there’s a PO discrepancy — wrong pricing, missing case documentation, incorrect SKU — the clock resets while someone digs through email threads to figure out what happened.
For distributors, the squeeze is one link further down the chain. Distributors don’t own the inventory — they earn commission after the manufacturer gets paid. So when hospital AP slows down, the manufacturer gets paid later. And when the manufacturer gets paid later, the distributor gets paid later. Two slow links instead of one. A surgery that took 45 minutes to complete can take 90–120 days to turn into a commission check — and that’s if the paperwork is clean on the first pass.
A mid-market manufacturer doing 300 cases a month through a distributor network can easily have $500K–$1M in completed but uncollected revenue at any given time. The distributors downstream are carrying weeks of earned but unpaid commissions — with no leverage over the hospital’s AP timeline and limited visibility into where the holdup actually is.
Now add tariffs to the picture. Nearly 70% of medical devices marketed in the U.S. are manufactured exclusively overseas. Trade-weighted U.S. tariff rates increased from about 2.2% to 16.9% between the start and middle of 2025. The cost increase lands on manufacturers first, but the reimbursement-compressed buyer has no room to absorb it. Distributors feel it as compressed margins on the products they sell. Someone eats the cost. Usually the smallest company in the chain.
What Financially Stressed Buyers Actually Do
There’s a pattern to how hospitals behave under financial pressure, and if you sell devices, you’ve probably already seen all three stages.
The audit. Your hospital account sends a spreadsheet asking you to justify every product they purchased in the last 12 months. Not clinical justification — economic justification. What did this implant save in OR time? In readmission rates? In length of stay? Most device companies don’t have that data organized at the account level. The ones that do have a conversation. The ones that don’t have a deadline.
The consolidation. The health system’s supply chain team runs a standardization initiative. Instead of four knee implant vendors, they want two. Instead of three trauma companies, one primary and one backup. The selection criteria aren’t purely clinical anymore. They include contract compliance rates, invoice accuracy, ease of ordering, and total cost of the commercial relationship — not just the cost of the product.
The silence. Reps stop getting callbacks. Not because the relationship is dead, but because the OR coordinator who used to take their calls is now handling 30% more administrative work with the same headcount. The surgeon who championed your product is seeing more patients to offset revenue per case. Nobody has bandwidth for a lunch meeting about your new product launch.
The Companies That Survive This
There’s a common argument that clinical credibility is the lifeline in a down market. That’s true on the sales side — the surgeon who trusts your product is still your best asset. But on the operations side, there’s an equally important filter that gets far less attention: operational credibility.
The device companies that survive a reimbursement squeeze aren’t necessarily the ones with the best clinical data. They’re the ones that are easiest to do business with.
That means invoices that match POs without manual reconciliation. Case documentation that’s complete before the bill goes out, not corrected after the fact. Inventory that can be located and accounted for without relying on reps to self-report. A commercial operation that doesn’t generate extra work for the hospital’s already-stretched staff.
The supply chain team evaluating which vendors to consolidate toward isn’t just comparing implant prices. They’re comparing the total cost of the relationship. A vendor who’s 5% cheaper on product but generates 20% more billing exceptions, back-and-forth emails, and reconciliation labor isn’t actually cheaper. They’re more expensive in a way that doesn’t show up on the GPO contract.
This is the operational version of the clinical credibility argument: your back office is now a competitive differentiator. Not because operations is glamorous — but because the buyer can no longer afford to subsidize your inefficiency.
What This Means for the Next 18 Months
The CMS conversion factor for 2026 technically increased — up 3.26% for non-APM participants, partly driven by the One Big Beautiful Bill Act’s 2.5% add-on. But most of that increase is offset by a finalized efficiency adjustment that reduces work RVUs by 2.5% across nearly all non-time-based codes. The net effect for most procedural specialties — the ones that use your devices — is close to flat or negative.
82% of surveyed physicians expect tariff-related expenses to raise hospital costs by at least 15%. Those hospitals are your customers. They’re not going to spend less on devices by choice — they’re going to be forced to, and the pressure will land on whoever is easiest to squeeze.
For manufacturers: the ones investing in operational infrastructure now — clean data, automated reconciliation, real-time inventory visibility — are building the competitive moat that GPO contracts alone can’t provide. Product differentiation gets you on the consideration list. Operational differentiation keeps you there when the CFO starts asking questions.
For distributors: the payment chain is only going to get longer. Every day between surgery and collected revenue is another day you’re waiting on two organizations upstream to close the loop. The distributors who push for cleaner case documentation, faster manufacturer invoicing, and fewer billing exceptions aren’t just speeding up their own commission checks — they’re becoming the kind of partner that both manufacturers and hospitals want to keep.
Clinical credibility gets you in the room. Operational credibility keeps you off the audit list.